Articles by Leah Lawrence
Benefits of CAR T-cell therapy outweigh the hypothetical future risk of secondary malignancies.
A new evaluation of the CLL-IPI revealed that its impact appears diminished in predicting OS in the era of targeted drugs.
The ELCLV3-21 high-risk signature distinguished those with MBL with a high probability of progression.
Using data from CLL long-term cultures, the researchers found that TBX21 expression was induced in CLL cells.
Early detection and prevention are particularly important in leukemia, Dr. Garcia-Manero explained.
Researchers are working to define and validate the ways in which mass spectrometry can aid in MM diagnosis and monitoring.
Shortages of essential drugs are not new, with one expert describing it as a “whack-a-mole” problem.
OS was still inversely proportional to the IPSS-M, but the molecular risk stratification had no additional prognostic power.
Here’s what they add to the treatment toolbox for hematologic malignancies.
Researchers and clinicians are attempting to make clinical trials better reflect the population of patients with MM.
Researchers presented updated data from the phase I XPORT-MF-034 trial at the Eleventh SOHO Annual Meeting.
The open-label ACE-536-MF-001 study included patient cohorts grouped by transfusion dependance and ruxolitinib therapy.
In PERSIST-2, treatment with pacritinib demonstrated a significant SVR benefit compared with the best available therapy, incl
Achieving event-free survival at 24 months using modern treatments was associated with improved OS.
Intratumoral hypoxia could be associated with CAR-T outcomes in patients with non-Hodgkin lymphoma.
The composition of T cells in patients with sMZL may affect the efficacy of T-cell-based therapies.
This single-center retrospective study looked at outcomes from 18 patients with AML treated with venetoclax plus an HMA.
The study included 59 patients with T-ALL with a median age of 20 at diagnosis.
The bispecific antibody mosunetuzumab in relapsed or refractory follicular lymphoma continues to show durable responses.
Researchers discuss how monitoring MRD in peripheral blood can aid in myeloma management.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.